US2013189292A1PendingUtilityA1

Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis and related proteins, peptides and compositions

46
Individually held — no corporate assignee on recordPriority: Mar 17, 2009Filed: Sep 22, 2011Published: Jul 25, 2013
Est. expiryMar 17, 2029(~2.6 yrs left)· nominal 20-yr term from priority
Inventors:Goran Hansson
A61P 9/10A61K 39/0005C07K 14/7051
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Immunostimulatory methods and systems for treating or preventing atherosclerosis and/or a condition associated thereto in an individual and related compounds and compositions.

Claims

exact text as granted — not AI-modified
1 .- 6 . (canceled) 
     
     
         7 . A method to treat and/or reduce the risk of atherosclerosis in an individual, the method comprising:
 immunizing the individual against one or more T cell receptors, the one or more T cell receptors comprising one or more a chains encoded by TRAV14, TRAV12, TRAV4 and/or a DNA sequence having at least 70% identity to TRAV14, TRAV12 or TRAV4 and/or one or more β chains encoded by TRBV 30, TRBV 31 and/or a DNA sequence having at least 70% identity to TRBV 30 or TRBV 31, wherein as a result of the immunizing, an immune response to the one or more T cell receptors is induced in the individual, thereby treating and/or reducing the risk of atherosclerosis in the individual.   
     
     
         8 . The method of  claim 7 , wherein the immunizing is performed by administering to the individual an immunogenic fragment of CDR2 variable region of TCR TRBV 31, an immunogenic fragment of CDR2 variable region of TCR TRBV30, an immunogenic fragment of TCR TRAV14, an immunogenic fragment of TCR TRAV12 and/or, an immunogenic fragment of TCR TRAV4. 
     
     
         9 . The method of  claim 7 , wherein the immunizing is performed by administering to the individual a peptide having at least 70% identity to sequence SEQ ID NO:1, SEQ ID NO:56, SEQ ID NO:58, or a combination thereof. 
     
     
         10 . The method of  claim 7 , wherein the immunizing is performed by administering to the individual a protein having at least 70% identify to sequence SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, or a combination thereof. 
     
     
         11 . (canceled) 
     
     
         12 . A vaccine for treatment and/or reduction of the risk of atherosclerosis, the vaccine comprising an immunogenic agent for a T cell receptor comprising an α chain encoded by TRAV 14, an α chain encoded by TRAV 12, an α chain encoded by TRAV4, and/or an α chain encoded by a DNA sequence having at least 70% identity to TRAV 14, TRAV 12 or TRAV 4. 
     
     
         13 . The vaccine of  claim 12 , wherein the T cell receptor further comprises a β chain encoded by TRBV 30, a β chain encoded by TRBV 31, and/or a β chain encoded by a DNA sequence having at least 70% identity to a peptide encoded by TRBV 30 or TRBV 31. 
     
     
         14 . The vaccine of  claim 13 , wherein the agent is a peptide having at least 70% identity to a peptide encoded by TCR TRVB 31. 
     
     
         15 . The vaccine of  claim 14 , wherein the agent is a peptide having at least 70% identity to sequence SEQ ID NO:1, SEQ ID NO:56 or SEQ ID NO:58 or a fragment thereof or a derivative thereof. 
     
     
         16 . The vaccine of  claim 13 , wherein the agent is a peptide having at least 70% identity to TCR TRVB30. 
     
     
         17 . The vaccine of  claim 12 , wherein the T cell receptor comprises an α chain encoded by TRAV 14 and the agent is a peptide having at least 70% identity to a protein encoded by TCR TRAV 14 (SEQ ID NO:63). 
     
     
         18 . The vaccine of  claim 17 , wherein the agent is a protein having at least 70% identity to sequence SEQ ID NO:63. 
     
     
         19 . The vaccine of  claim 12 , wherein the T cell receptor comprises an α chain encoded by TRAV 12 and the agent is a peptide having at least 70% identity to a protein encoded by TCR TRAV 12. 
     
     
         20 . The vaccine of  claim 19 , wherein the agent is a protein having at least 70% identity to sequence SEQ ID NO:66. 
     
     
         21 . The vaccine of  claim 12 , wherein the T cell receptor comprises an α chain encoded by TRAV4 and the agent is a peptide having at least 70% identity to a protein encoded by TCR TRAV4 (SEQ ID NO:69). 
     
     
         22 . The vaccine of  claim 21 , wherein the agent is a protein having at least 70% identity to sequence SEQ ID NO:69. 
     
     
         23 .- 42 . (canceled)

Join the waitlist — get patent alerts

Track US2013189292A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.